Impact
Finding lung cancer sooner, for more people.
Lung cancer takes more lives than any other cancer, largely because it is found late. Pulma is built to make an early first check easy enough for anyone to take.
Why It Matters
Early lung cancer rarely causes symptoms, so many cases are only found after the disease has spread. Screening today relies on low-dose CT scans, which need a hospital visit and specialist equipment — barriers that keep many people from ever being checked.
new lung cancer cases worldwide in 2022 — the most commonly diagnosed cancer.
deaths from lung cancer in 2022, making it the leading cause of cancer death.
five-year survival for non-small cell lung cancer found early, versus after it has spread.
Sources: GLOBOCAN 2022, Global Cancer Statistics (CA Cancer J Clin, 2024); American Cancer Society, Lung Cancer Survival Rates.
Why Pulma
A first check that removes the barriers to getting screened.
Non-invasive
Just breathe into the device — no needles and no radiation.
Fast
A 10-second breath sample, with the result shown right in the app.
Portable
A handheld device and a phone are all it takes — at a clinic, in the community or at home.
Trackable
Every scan is saved, so changes over time are easy to see and share with a doctor.
Who We Aim to Help
People at higher risk
Smokers, former smokers and people exposed to second-hand smoke or air pollution can check regularly and track changes.
Communities far from hospitals
A portable device that only needs a phone brings a first check to places where CT scanners and specialists are hard to reach.
Clinicians
A quick, non-invasive first check can help decide who should be prioritised for a full clinical assessment.
Clinical Deployment
Pulma has been taken into a hospital Oncology and Hematology Center, where our team demonstrated the device and app to physicians. Their feedback guides how we refine Pulma for clinical settings.